Anthracyclines, HER2-targeted therapies, immune checkpoint inhibitors, and newer tyrosine kinase inhibitors have all been implicated in various forms of cardiotoxicity, through mechanisms ranging from direct myocardial injury to endothelial dysfunction and inflammation. The gene discussed is ERBB2; the disease is endothelial dysfunction.